Carlo Lovati

List of Publications by Year
in descending order

41	991	516710 16	434195 31
papers	citations	h-index	g-index

41	41	41	1781
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience. Journal of Neurology, 2022, 269, 5848-5857.	3.6	17
2	Binaural stimulation in migraine: preliminary results from a 3-month evening treatment. Neurological Sciences, 2019, 40, 197-198.	1.9	4
3	Cerebral blood flow in migraine without aura: ASL-MRI case control study. Neurological Sciences, 2019, 40, 183-184.	1.9	6
4	Cerebral venous outflow in migraine. Neurological Sciences, 2019, 40, 181-182.	1.9	3
5	Validation of a self-reported instrument to assess work-related difficulties in patients with migraine: the HEADWORK questionnaire. Journal of Headache and Pain, 2018, 19, 85.	6.0	19
6	May migraine attack response to triptans be a predictor of the efficacy of Onabotulinum toxin-A prophylaxis?. Neurological Sciences, 2018, 39, 153-154.	1.9	8
7	The evaluation of difficulties with work-related activities caused by migraine: towards a specific questionnaire. Neurological Sciences, 2018, 39, 131-133.	1.9	4
8	Personality traits in migraineurs: a case-control study by personality inventory for DSM-5 (PID-5). Neurological Sciences, 2018, 39, 129-130.	1.9	5
9	The brain effect of the migraine attack: an ASL MRI study of the cerebral perfusion during a migraine attack. Neurological Sciences, 2018, 39, 73-74.	1.9	8
10	The possible influence of foramen ovale and obstructive sleep apnoeas on trigeminal autonomic cephalalgias: preliminary results of a ANIRCEF-PROGRAN study. Neurological Sciences, 2018, 39, 81-82.	1.9	0
11	Action mechanisms of Onabotulinum toxin-A: hints for selection of eligible patients. Neurological Sciences, 2017, 38, 131-140.	1.9	13
12	Sleep, headaches and cerebral energy control: a synoptic view. Expert Review of Neurotherapeutics, 2017, 17, 239-250.	2.8	5
13	Brain plasticity and migraine transformation: fMRI evidences. Expert Review of Neurotherapeutics, 2016, 16, 1413-1425.	2.8	11
14	Sleep apnea headache and headaches with sleep apnea: the importance of being secondary. Expert Review of Neurotherapeutics, 2013, 13, 1135-1137.	2.8	3
15	Central sensitization in photophobic and non-photophobic migraineurs: possible role of retino nuclear way in the central sensitization process. Neurological Sciences, 2013, 34, 133-135.	1.9	17
16	Sleep and headache: a bidirectional relationship. Expert Review of Neurotherapeutics, 2010, 10, 105-117.	2.8	32
17	APOE Îµ2 and Îµ4 influence the susceptibility for Alzheimer's disease but not other dementias. International Journal of Molecular Epidemiology and Genetics, 2010, 1, 193-200.	0.4	12
18	The Serotonin Transporter Promoter Polymorphic Region is not a Risk Factor for Alzheimer's Disease Related Behavioral Disturbances. Journal of Alzheimer's Disease, 2009, 18, 125-130.	2.6	13

#	Article	IF	Citations
19	Allodynia in migraine: frequent random association or unavoidable consequence?. Expert Review of Neurotherapeutics, 2009, 9, 395-408.	2.8	42
20	Serotonin Transporter Gene Polymorphic Element <i>5-HTTLPR</i> Increases the Risk of Sporadic Parkinsonâ€™s Disease in Italy. European Neurology, 2009, 62, 120-123.	1.4	15
21	Is allodynia influenced by psychological profile in headache patients?. Neurological Sciences, 2009, 30, 113-115.	1.9	4
22	Acute and Interictal Allodynia in Patients With Different Headache Forms: An Italian Pilot Study. Headache, 2008, 48, 272-277.	3.9	56
23	Personality profile and allodynic migraine. Neurological Sciences, 2008, 29, 152-154.	1.9	10
24	Association study to evaluate the serotonin transporter and apolipoprotein E genes in frontotemporal lobar degeneration in Italy. Journal of Human Genetics, 2008, 53, 1029-1033.	2.3	8
25	Interaction between the APOE É›4 allele and the APH-1b c+651T>G SNP in Alzheimer's disease. Neurobiology of Aging, 2008, 29, 1494-1501.	3.1	7
26	Absence of TREM2 polymorphisms in patients with Alzheimer's disease and Frontotemporal Lobar Degeneration. Neuroscience Letters, 2007, 411, 133-137.	2.1	18
27	Serum folate concentrations in patients with cortical and subcortical dementias. Neuroscience Letters, 2007, 420, 213-216.	2.1	11
28	The urokinase-type plasminogen activator polymorphism PLAU_1 is a risk factor for APOE-Îµ4 non-carriers in the Italian Alzheimerâ€™s disease population and does not affect the plasma AÎ²(1â€“42) level. Neurobiology of Disease, 2007, 25, 609-613.	4.4	9
29	Spinocerebellar ataxia type 17 (SCA17): Oculomotor phenotype and clinical characterization of 15 Italian patients. Journal of Neurology, 2007, 254, 1538-1546.	3.6	78
30	A novel polymorphism in SEL1L confers susceptibility to Alzheimer's disease. Neuroscience Letters, 2006, 398, 53-58.	2.1	24
31	Candidate gene analysis of IP-10 gene in patients with Alzheimer's disease. Neuroscience Letters, 2006, 404, 217-221.	2.1	17
32	Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiology of Aging, 2006, 27, 1763-1768.	3.1	185
33	Plasma levels of beta-amyloid (1â€“42) in Alzheimer's disease and mild cognitive impairment. Neurobiology of Aging, 2006, 27, 904-905.	3.1	97
34	Association of neuronal nitric oxide synthase C276T polymorphism with Alzheimerâ€™s disease. Journal of Neurology, 2005, 252, 985-986.	3.6	17
35	Apolipoprotein E haplotyping by denaturing high-performance liquid chromatography. Clinical Chemistry and Laboratory Medicine, 2005, 43, 512-8.	2.3	12
36	The T-786C NOS3 polymorphism in Alzheimer's disease: Association and influence on gene expression. Neuroscience Letters, 2005, 382, 300-303.	2.1	26

#	Article	IF	Citations
37	P-selectin glycoprotein ligand-1 variable number of tandem repeats (VNTR) polymorphism in patients with multiple sclerosis. Neuroscience Letters, 2005, 388, 149-152.	2.1	13
38	DNA sequence variations in the prolyl isomerase Pin1 gene and Alzheimer's disease. Neuroscience Letters, 2005, 389, 66-70.	2.1	14
39	Influence of the Glu298Asp polymorphism of NOS3 on age at onset and homocysteine levels in AD patients. Neurobiology of Aging, 2005, 26, 789-794.	3.1	36
40	CCR2-64I polymorphism and CCR5Î”32 deletion in patients with Alzheimer's disease. Journal of the Neurological Sciences, 2004, 225, 79-83.	0.6	35
41	MCP-1 in Alzheimerâ€™s disease patients: A-2518G polymorphism and serum levels. Neurobiology of Aging, 2004, 25, 1169-1173.	3.1	77